Cancer Immunotherapy Conference Agenda

 

Day 1

 

7:30

Registration

8:00

Opening Remarks

8:05

Keynote Address: Immunotherapy: New Era in Cell Therapy: From CAR-T to Solid Tumor

Renier Brentjens, M.D., Ph.D.
Director–Cellular Therapies
Memorial Sloan Kettering

Session I

Adoptive Cell Therapies

8:50

Keynote II: Building a Leader in Cell Therapy—Challenges Facing Clinical and Commercial Strategies

Pascal Touchon, D.V.M.
Senior Vice President, Global Head–Cell and Gene
Novartis Oncology

9:30

Recap and Q&A

9:40

Novel CARs and TCRs

Helen Tayton-Martin, Ph.D.
Chief Business Officer
Adaptimmune Therapeutics plc

Christian Itin, Ph.D.
Chief Executive Officer and Chairman of the Board of Directors
Autolus Limited

10:20

Coffee Break

10:40

Allogenic Platforms

Andre Koulika, Ph.D.
Chief Executive Officer
Cellectis SA

Chris Haqq, M.D., Ph.D.
Executive Vice President and Chief Scientific Officer
Atara Biotherapeutics, Inc.

11:20

Other Cell Types (NK and TILs)

Bob Valamehr, Ph.D.
Vice President–Immunotherapy
Fate Therapeutics, Inc.

Maria Fardis, Ph.D.
Chief Executive Officer
Iovance Biotherapeutics, Inc. .

12:00

Safety Issues of Cell Therapies

David Spencer, Ph.D.
Chief Scientific Officer
Bellicum Pharmaceuticals, Inc.

Company to be confirmed

12:40

Lunch Panel: Setting Up Commercial Cell Therapy Products in Academic Center / Q&A and Recap

Sergio Giralt, M.D.
Chief, Adult Bone Marrow Transplant Service
Melvin Berlin Family Chair in Multiple Myeloma
Memorial Sloan Kettering Cancer Center


 

Session II

Jump Starting the Immune System

1:40

Cancer Therapeutic Vaccines Overview

Col. (ret.) George E. Peoples, M.D., F.A.C.S., MC, USA
Founder and CEO, Cancer Insight, LLC;
Director–Cancer Vaccine Development Program, Metis Foundation;
Professor of Surgery, Uniformed Services University;
Professor (adjunct) of Surgical Oncology, MD Anderson Cancer Center

2:00

Oncolytic Viruses

Oncolytic Viruses Making Tumors Hot
Robert H.I. Andtbacka, M.D., C.M., F.A.C.S., F.R.C.S.C.
Associate Professor, Surgical Oncology
Department of Surgery University of Utah
Co-Director Melanoma Program
Co-Director Melanoma Clinical Research Program
Huntsman Cancer Institute

Mike Burgess, MBChB, Ph.D.
President of R&D
Turnstone Biologics

2:40

In Situ Vaccination

Joshua Brody, M.D.
Director–Lymphoma Immunotherapy Program
Icahn School of Medicine at Mount Sinai, Hess Center for Science
and Medicine

3:05

Q&A and Recap

3:20

Coffee Break

4:05

STING

R.P. “Kris” Iyer, Ph.D.
Chief Scientific Officer
Spring Bank Pharmaceuticals

Aduro Biotech, Inc
Speaker to be confirmed

4:35

Cytokines

Deborah Charych, Ph.D.
Executive Director – Research and Development
Nektar Therapeutics

4:55

Q&A and Recap

5:10

Reception



 

Day 2

 

7:30

Registration

8:00

Opening Remarks

8:05

Keynote III: Personalized IO and How to Efficiently Strategize Combo Trials

Ira Mellman, Ph.D. Vice President–Cancer Immunology Genentech, Inc.

Session III

Next generation approaches

8:50

Neoantigens

John Castle, Ph.D.
Head–Translational Medicine and Bioinformatics
Agenus Inc.

Company to be confirmed

9:20

Keynote IV: Optimizing the Immune Microenvironment in Prostate Cancer

Ravi Madan, M.D.
Clinical Director–Genitourinary Malignancies Branch
Center for Cancer Research, National Cancer Institute

10:00

Q&A and Recap

10:15

Coffee Break

10:30

Tumor Microenvironment: MDSCs and Tregs
The Tumor Microenvironment in Cancer: Reevaluating Checkpoints on Suppressive Myeloid Cells

 

Catherine Sabatos–Peyton, Ph.D.
Director of Exploratory Immuno-Oncology
Novartis Institutes for Biomedical Research
Title to be confirmed
Jeff Kutok, Ph.D.
Chief Scientific Officer
Infinity Pharmaceuticals, Inc.

11:10

Tumor Microenvironment: Metabolites/Enzymes

 

Charles Link Jr. M.D.
Chief Executive Officer
NewLink Genetics Corporation
Calithera Biosciences, Inc.
Speaker to be confirmed

11:50

Q&A and Recap


 

Session IV

Immunotherapy Combinations

12:05

Lunch Panel: Economics of Immunotherapies and Immunotherapy Combinations

Bryon Wornson, moderator
Vice President–Global Health and Value
Pfizer Inc.

1:00

Keynote V:
Clinical Combination Strategies in Immunotherapy

Roger Dansey, M.D.
Senior Vice President–Global Clinical Development Oncology
Merck Research Laboratories, Merck & Co.

1:40

Lilly Rational Combinations in Immuno-Oncology

Michael Kalos Ph.D.
Chief Scientific Officer–Cancer Immunobiology
Lilly Research Laboratories, Eli Lilly & Company

2:00

Targeted Therapy Combinations With Immunotherapy

Chris Boshoff, M.D., Ph.D.
Senior Vice President and Head of Immuno-Oncology, Early Development and Translational Oncology
Pfizer Inc.

2:20

Q&A and Recap

2:35

Coffee Break

2:50

Personalized Immunotherapy for NSCLC

Roy Hersbt, M.D., Ph.D.
Ensign Professor of Medicine (Oncology), Chief–Medical Oncology, Associate Director–Translational Research, Director–Thoracic Oncology Research Program
Yale Comprehensive Cancer Center, Yale School of Medicine

3:15

Immunotherapy Combinations for Renal Cell or Urothelial Carcinoma

Andrea Apolo, M.D.
Investigator–Genitourinary Malignancies Branch, Head–Bladder Cancer Section, NIH Lasker Clinical Research Scholar
Center for Cancer Research, NIH

3:40

Portfolio Approach

 

Speaker to be confirmed
BeiGene, Ltd.

3:55

Microbiome in IO

Company / speaker to be confirmed
J.C. Gutiérrez-Ramos, Ph.D.
Chief Executive Officer
Synlogic

4:30

Bispecifics

Ton Logtenberg, Ph.D.
Chief Executive Officer
Merus N.V.
Louis Matis, M.D.
Senior Vice President and Chief Development Officer
Pieris Pharmaceuticals, Inc.

5:00

Q&A and Recap

5:15

Reception


 

Speakers

 

Andtbacka 

Robert H.I. Andtbacka, M.D., C.M., F.A.C.S., F.R.C.S.C.
Associate Professor, Surgical Oncology
Department of Surgery
University of Utah
Co-Director Melanoma Program
Co-Director Melanoma Clinical Research Program
Huntsman Cancer Institute

Apolo

Andrea Apolo, M.D.
Investigator–Genitourinary Malignancies Branch, Head–Bladder Cancer Section, NIH Lasker Clinical Research Scholar
Center for Cancer Research, NIH

Boshoff 

Chris Boshoff, M.D., Ph.D.
Senior Vice President and Head of Immuno-Oncology, Early Development and Translational Oncology
Pfizer Inc.

Brentjens 

Renier Brentjens, M.D., Ph.D.
Director–Cellular Therapies
Memorial Sloan Kettering

Brody 

Joshua Brody, M.D.
Director–Lymphoma Immunotherapy Program
Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine

Burgess 

Mike Burgess, MBChB, Ph.D.
President of R&D
Turnstone Biologics

Castle 

John Castle, Ph.D.
Head–Translational Medicine and Bioinformatics
Agenus Inc.

Charych 

Deborah Charych, Ph.D.
Executive Director – Research and Development
Nektar Therapeutics

Coffman 

Robert Coffman, Ph.D.
Senior Vice President and Chief Scientific Officer Dynavax Technologies Corporation

Dansey 

Roger Dansey, M.D.
Senior Vice President–Global Clinical Development Oncology Merck Research Laboratories, Merck & Co.

Fardis 

Maria Fardis, Ph.D.
Chief Executive Officer
Iovance Biotherapeutics, Inc.

Giralt 

Sergio Giralt, M.D.
Chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma
Memorial Sloan Kettering Cancer Center

Gutierrez 

J.C. Gutiérrez-Ramos, Ph.D.
Chief Executive Officer
Synlogic

Haqq 

Chris Haqq, M.D., Ph.D.
Executive Vice President and Chief Scientific Officer
Atara Biotherapeutics, Inc.

Herbst 

Roy Hersbt, M.D., Ph.D.
Ensign Professor of Medicine (Oncology), Chief–Medical Oncology, Associate Director–Translational Research, Director–Thoracic Oncology Research Program
Yale Comprehensive Cancer Center, Yale School of Medicine

Horobin 

Joanna Horobin, M.D.
Chief Medical Officer
Idera Pharmaceuticals, Inc.

Itin 

Christian Itin, Ph.D.
Chief Executive Officer and Chairman of the Board of Directors
Autolus Limited

Iyer 

R.P. “Kris” Iyer, Ph.D.
Chief Scientific Officer
Spring Bank Pharmaceuticals

Kalos 

Michael Kalos, Ph.D.
Chief Scientific Officer–Cancer Immunobiology Lilly Research
Laboratories, Eli Lilly & Company

Koulika 

Andre Koulika, Ph.D.
Chief Executive Officer
Cellectis SA

Kutok 

Jeff Kutok, Ph.D.
Chief Scientific Officer
Infinity Pharmaceuticals, Inc.

Link 

Charles Link Jr., M.D.
Chief Executive Officer
NewLink Genetics Corporation

Logtenberg 

Ton Logtenberg, Ph.D.
Chief Executive Officer
Merus N.V.

Madan 

Ravi Madan, M.D.
Clinical Director–Genitourinary Malignancies Branch
Center for Cancer Research, National Cancer Institute

Matis 

Louis Matis, M.D.
Senior Vice President and Chief Development Officer
Pieris Pharmaceuticals, Inc.

Mellman 

Ira Mellman, Ph.D.
Vice President–Cancer Immunology
Genentech, Inc.

Peoples 

Col. (ret.) George E. Peoples, M.D., FACS, MC, USA, Col. (ret.) George E. Peoples, M.D., FACS, MC, USA
Founder and CEO, Cancer Insight, LLC; Director–Cancer Vaccine Development Program, Metis Foundation; Professor of Surgery, Uniformed Services University; Professor (adjunct) of Surgical Oncology, MD Anderson Cancer Center

Sabatos-Peyton 

Catherine Sabatos-Peyton, Ph.D.
Director of Exploratory Immuno-Oncology
Novartis Institutes for Biomedical Research

Spencer 

David Spencer, Ph.D.
Chief Scientific Officer
Bellicum Pharmaceuticals, Inc..

Tayton-Martin 

Helen Tayton-Martin, Ph.D.
Chief Business Officer
Adaptimmune Therapeutics plc

Touchon 

Pascal Touchon, D.V.M.
Senior Vice President, Global Head–Cell and Gene
Novartis Oncology

Valamehr 

Bob Valamehr, Ph.D.
Vice President–Immunotherapy
Fate Therapeutics, Inc.

Wornson

Bryon Wornson
Vice President–Global Health and Value
Pfizer Inc.